For the quarter ended December 2025, LivaNova (LIVN) reported revenue of $360.9 million, up 12.2% over the same period last year. EPS came in at $0.86, compared to $0.81 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $350.93 million, representing a surprise of +2.84%. The company delivered an EPS surprise of +7.06%, with the consensus EPS estimate being $0.80.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how LivaNova performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Neuromodulation: $152.7 million compared to the $149.13 million average estimate based on two analysts.
- Net Sales- Cardiopulmonary: $206.6 million compared to the $200.66 million average estimate based on two analysts.
- Net Sales- Other: $1.6 million compared to the $1.89 million average estimate based on two analysts.
View all Key Company Metrics for LivaNova here>>>
Shares of LivaNova have returned +7.7% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LivaNova PLC (LIVN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
